Today, Congresswoman Nikki Budzinski (IL-13) hosted a roundtable with independent pharmacists, pharmacy students and faculty ...
For example, the big-three PBMs are the dominant middlemen in drug transactions, and they’re each part of a company that also owns a top-10 insurer. So they could try to get better deals for their ...
It remains to be seen how well President Joe Biden’s Inflation Reduction Act will actually work in lowering prescription drug ...
No matter what happens in this election, the government should work for the people. The government may not be perfect, but it ...
The owner of one of the three largest pharmacy middlemen in the United States last month filed suit to quash an attempt by the Federal Trade Commission to investigate industry ...
KFF Health News on MSN5d
What’s at Stake: A Pivotal Election for Six Big Health IssuesThe election could have major impacts on drug prices, Medicaid, the Affordable Care Act, public health agencies, abortion, ...
A drug pricing expert reveals the shocking cost disparity of a life-saving spinal muscular atrophy drug in India, priced at ...
Elizabeth Warren seeks scrutiny of deals that would allow drug middlemen McKesson, Cardinal Health, and Cencora to also ...
Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...
Congresswoman Nikki Budzinski (IL-13) will host a roundtable discussion with independent pharmacists on Saturday, November 2, ...
10d
Huge health conglomerates have another reason to worry that their business model might be disrupted. On a visit to Columbus, ...
PBMs represent insurers in drug transactions, and they decide which medicines will be covered. And, because just three PBMs control access to about 80% of insured patients, they have enormous ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback